CA2381302A1 - Drug for treating fractures - Google Patents
Drug for treating fractures Download PDFInfo
- Publication number
- CA2381302A1 CA2381302A1 CA002381302A CA2381302A CA2381302A1 CA 2381302 A1 CA2381302 A1 CA 2381302A1 CA 002381302 A CA002381302 A CA 002381302A CA 2381302 A CA2381302 A CA 2381302A CA 2381302 A1 CA2381302 A1 CA 2381302A1
- Authority
- CA
- Canada
- Prior art keywords
- bone
- drug
- bisphosphonate
- group
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ2325A AUPQ232599A0 (en) | 1999-08-19 | 1999-08-19 | Drug for treating fractures |
AUPQ2325 | 1999-08-19 | ||
PCT/AU2000/000982 WO2001013922A1 (en) | 1999-08-19 | 2000-08-17 | Drug for treating fractures |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2381302A1 true CA2381302A1 (en) | 2001-03-01 |
Family
ID=3816500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002381302A Abandoned CA2381302A1 (en) | 1999-08-19 | 2000-08-17 | Drug for treating fractures |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1214079A4 (hu) |
JP (1) | JP2003507426A (hu) |
KR (1) | KR20020027562A (hu) |
CN (1) | CN100345548C (hu) |
AU (1) | AUPQ232599A0 (hu) |
BR (1) | BR0013416A (hu) |
CA (1) | CA2381302A1 (hu) |
HK (1) | HK1048441B (hu) |
HU (1) | HUP0202396A3 (hu) |
IL (1) | IL148166A0 (hu) |
NO (1) | NO20020784L (hu) |
NZ (1) | NZ517538A (hu) |
PL (1) | PL353485A1 (hu) |
SK (1) | SK2382002A3 (hu) |
WO (1) | WO2001013922A1 (hu) |
ZA (1) | ZA200202160B (hu) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0116862A (pt) | 2001-02-06 | 2004-01-13 | Royal Alexandra Hosp Children | Medicamento, métodos para tratar um paciente com osteonecrose e/ou osteocondrite dissecans, para prevenir a osteonecrose e/ou osteocondrite dissecans em um paciente em risco de cada uma das ditas doenças, uso de um medicamento, e, método para prevenir a destruição da cartilagem ou condrólise associadas com osteonecrose e/ou osteocondrite dissecans |
WO2002080933A1 (en) * | 2001-04-03 | 2002-10-17 | The Royal Alexandra Hospital For Children | A drug for use in bone grafting |
AUPR553701A0 (en) * | 2001-06-07 | 2001-07-12 | Royal Alexandra Hospital For Children, The | A device for the delivery of a drug to a fractured bone |
ES2561463T3 (es) * | 2003-08-21 | 2016-02-26 | Addbio Ab | Dispositivo de implante recubierto con bisfosfonato y método para el mismo |
NZ545804A (en) * | 2003-09-19 | 2009-09-25 | Wisconsin Alumni Res Found | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate |
ITMI20040218A1 (it) * | 2004-02-10 | 2004-05-10 | Abiogen Pharma Spa | Uso di neridronato sodico per promuovere la neoformazione ossea |
ITMI20040641A1 (it) * | 2004-03-31 | 2004-06-30 | Tb Technology S R L | Composizioni bioadesive bifunzionali per implantologia orale |
AR048742A1 (es) * | 2004-12-22 | 2006-05-24 | Gador Sa | Sistema de aplicacion de medicamentos intra-oral |
US8940320B2 (en) | 2005-10-27 | 2015-01-27 | Thommen Medical Ag | Dental implant and production method for said implant |
US8882740B2 (en) | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
CN114532937A (zh) * | 2020-11-18 | 2022-05-27 | 中国人民解放军海军军医大学第一附属医院 | 一种小肠镜辅助装置 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR8107560A (pt) * | 1981-11-19 | 1983-07-05 | Luiz Romariz Duarte | Estimulacao ultra-sonica da consolidacao de fraturas osseas |
JPH07502507A (ja) * | 1991-12-17 | 1995-03-16 | プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド | ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法 |
AU670337B2 (en) * | 1992-11-30 | 1996-07-11 | Novartis Ag | Use of certain methanebisphosphonic acid derivatives in fracture healing |
EP0600834A1 (en) * | 1992-11-30 | 1994-06-08 | Ciba-Geigy Ag | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing |
EP0675723A4 (en) * | 1992-12-23 | 1998-08-05 | Merck & Co Inc | BIPHOSPHONATE / ESTROGEN THERAPY FOR TREATING AND PREVENTING BONE LOSS. |
US5403829A (en) * | 1993-03-24 | 1995-04-04 | Leiras Oy | Use of bisphosphonates in endo-osteal bone surgery |
US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
GB9408775D0 (en) * | 1994-05-04 | 1994-06-22 | Ciba Geigy Ag | Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration |
CA2221416A1 (en) * | 1995-06-06 | 1996-12-12 | Merck & Co., Inc. | Bisphosphonate therapy for bone loss associated with rheumatoid arthritis |
US5616571A (en) * | 1995-06-06 | 1997-04-01 | Merck & Co., Inc. | Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
US5853759A (en) * | 1996-05-17 | 1998-12-29 | Merck & Co.. Inc. | Effervescent alendronate formulation |
GB9613722D0 (en) * | 1996-06-28 | 1996-08-28 | Univ Liverpool | Chemical compounds |
-
1999
- 1999-08-19 AU AUPQ2325A patent/AUPQ232599A0/en not_active Abandoned
-
2000
- 2000-08-17 HU HU0202396A patent/HUP0202396A3/hu unknown
- 2000-08-17 CN CNB008117659A patent/CN100345548C/zh not_active Expired - Fee Related
- 2000-08-17 IL IL14816600A patent/IL148166A0/xx unknown
- 2000-08-17 KR KR1020027002160A patent/KR20020027562A/ko not_active Application Discontinuation
- 2000-08-17 JP JP2001518059A patent/JP2003507426A/ja active Pending
- 2000-08-17 WO PCT/AU2000/000982 patent/WO2001013922A1/en active IP Right Grant
- 2000-08-17 CA CA002381302A patent/CA2381302A1/en not_active Abandoned
- 2000-08-17 PL PL00353485A patent/PL353485A1/xx not_active Application Discontinuation
- 2000-08-17 EP EP00952791A patent/EP1214079A4/en not_active Withdrawn
- 2000-08-17 SK SK238-2002A patent/SK2382002A3/sk not_active Application Discontinuation
- 2000-08-17 BR BR0013416-3A patent/BR0013416A/pt not_active Application Discontinuation
- 2000-08-17 NZ NZ517538A patent/NZ517538A/en unknown
-
2002
- 2002-02-18 NO NO20020784A patent/NO20020784L/no not_active Application Discontinuation
- 2002-03-15 ZA ZA200202160A patent/ZA200202160B/en unknown
-
2003
- 2003-01-21 HK HK03100502.8A patent/HK1048441B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO20020784D0 (no) | 2002-02-18 |
PL353485A1 (en) | 2003-11-17 |
HK1048441B (zh) | 2008-02-22 |
BR0013416A (pt) | 2002-04-30 |
HK1048441A1 (en) | 2003-04-04 |
AUPQ232599A0 (en) | 1999-09-09 |
JP2003507426A (ja) | 2003-02-25 |
NO20020784L (no) | 2002-02-18 |
HUP0202396A2 (hu) | 2002-11-28 |
CN100345548C (zh) | 2007-10-31 |
WO2001013922A1 (en) | 2001-03-01 |
EP1214079A4 (en) | 2004-03-24 |
EP1214079A1 (en) | 2002-06-19 |
ZA200202160B (en) | 2003-08-27 |
CN1370071A (zh) | 2002-09-18 |
HUP0202396A3 (en) | 2005-02-28 |
NZ517538A (en) | 2003-07-25 |
KR20020027562A (ko) | 2002-04-13 |
SK2382002A3 (en) | 2002-09-10 |
IL148166A0 (en) | 2002-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yıldız et al. | Effect of zoledronic acid on osseointegration of titanium implants: an experimental study in an ovariectomized rabbit model | |
WO2002098307A1 (en) | A device for the delivery of a drug to a fractured bone | |
Little et al. | Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis: A study in immature rabbits | |
US20040157798A1 (en) | Drug for use in bone grafting | |
JPH09512268A (ja) | 整形外科的人工器官移植後の骨吸収を阻害するためのビスホスホネートの使用 | |
JPH08510996A (ja) | 骨の手術へのビスホスホネートの使用 | |
CA2381302A1 (en) | Drug for treating fractures | |
Tudor et al. | Static and dynamic periosteal elevation: a pilot study in a pig model | |
Pampu et al. | Experimental evaluation of the effects of zoledronic acid on regenerate bone formation and osteoporosis in mandibular distraction osteogenesis | |
NO310057B1 (no) | Anvendelse av visse metanbisfosfonsyrederivater for å forhindre lösning av protese og protesemigrering | |
Küçük et al. | Comparison of local and systemic alendronate on distraction osteogenesis | |
AU5973496A (en) | Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices | |
Little et al. | Effect of pamidronate on distraction osteogenesis and fixator-related osteoporosis | |
EP2953632A1 (en) | Amorphous calcium carbonate for accelerated bone growth | |
Tarvainen et al. | Effect of clodronate on fracture healing in denervated rats | |
Harding et al. | A single dose zoledronic acid enhances pin fixation in high tibial osteotomy using the hemicallotasis technique. A double-blind placebo controlled randomized study in 46 patients | |
AU781068B2 (en) | Drug for treating fractures | |
CA2353528C (en) | Use of ibandronate for promoting osseointegration of endoprostheses | |
Kurth et al. | Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat | |
Goodship et al. | Prevention of strain‐related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate | |
Alshahrani et al. | Ranitidine impairs bone healing and implant osseointegration in rats' tibiae | |
Kakar et al. | Can we improve fixation and outcomes in the treatment of femoral neck fractures? The use of pharmaceuticals | |
Saghieh et al. | The impact of zoledronic acid on regenerate and native bone after consolidation and removal of the external fixator: an animal model study | |
JP2010526064A (ja) | 骨組織の成長の育成および保存のための方法および組成物 | |
Heidari et al. | Effect of risedronate on bone resorption during the consolidation phase of distraction osteogenesis: a rabbit model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |